Cerus (NASDAQ:CERS) Director Eric Bjerkholt Sells 20,454 Shares

Posted by Geri Gentry on Jun 11th, 2026

Cerus Corporation (NASDAQ:CERS – Get Free Report) Director Eric Bjerkholt sold 20,454 shares of the firm’s stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $2.60, for a total transaction of $53,180.40. Following the sale, the director owned 261,679 shares in the company, valued at approximately $680,365.40. The trade was a 7.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Cerus Stock Up 1.2%

Shares of NASDAQ:CERS traded up $0.03 during midday trading on Thursday, reaching $2.59. 3,859,203 shares of the company were exchanged, compared to its average volume of 2,282,825. Cerus Corporation has a fifty-two week low of $1.15 and a fifty-two week high of $3.15. The company has a quick ratio of 1.06, a current ratio of 1.63 and a debt-to-equity ratio of 0.47. The stock has a fifty day simple moving average of $2.34 and a two-hundred day simple moving average of $2.20. The firm has a market cap of $518.96 million, a PE ratio of -51.80 and a beta of 1.77.

Cerus (NASDAQ:CERS – Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The biotechnology company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.02. Cerus had a negative net margin of 4.41% and a negative return on equity of 15.18%. The business had revenue of $59.89 million for the quarter, compared to analyst estimates of $55.68 million. As a group, sell-side analysts forecast that Cerus Corporation will post -0.02 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. Captrust Financial Advisors grew its position in Cerus by 15.3% in the fourth quarter. Captrust Financial Advisors now owns 37,051 shares of the biotechnology company’s stock valued at $76,000 after purchasing an additional 4,916 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Cerus by 1.1% in the 1st quarter. Bank of New York Mellon Corp now owns 507,455 shares of the biotechnology company’s stock valued at $924,000 after acquiring an additional 5,365 shares during the period. Wealth Enhancement Advisory Services LLC grew its position in shares of Cerus by 8.1% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 81,556 shares of the biotechnology company’s stock valued at $169,000 after acquiring an additional 6,094 shares during the period. Engineers Gate Manager LP grew its position in shares of Cerus by 4.7% in the 4th quarter. Engineers Gate Manager LP now owns 142,958 shares of the biotechnology company’s stock valued at $294,000 after acquiring an additional 6,415 shares during the period. Finally, Stephens Inc. AR grew its position in shares of Cerus by 6.9% in the 1st quarter. Stephens Inc. AR now owns 103,192 shares of the biotechnology company’s stock valued at $188,000 after acquiring an additional 6,651 shares during the period. Institutional investors own 78.37% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Zacks Research raised shares of Cerus from a “strong sell” rating to a “hold” rating in a research report on Thursday, April 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cerus in a research report on Wednesday, March 25th. Wall Street Zen raised shares of Cerus from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Finally, BTIG Research raised shares of Cerus from a “neutral” rating to a “buy” rating and set a $4.00 target price for the company in a research report on Friday, May 1st. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $4.00.

Get Our Latest Stock Analysis on Cerus

Cerus Company Profile

(Get Free Report)

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.